NCT02219256View on ClinicalTrials.gov

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Autoimmune Disease
Interventions
DRUG

TAK-079

TAK-079 solution

DRUG

Placebo to TAK-079

Placebo to TAK-079 solution

Trial Locations (2)

Unknown

London

Headington

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY